DOXIMITY INC-CLASS A (DOCS)
US26622P1075 - Common Stock
Overall DOCS gets a fundamental rating of 7 out of 10. We evaluated DOCS against 40 industry peers in the Health Care Technology industry. DOCS scores excellent points on both the profitability and health parts. This is a solid base for a good stock. DOCS is not priced too expensively while it is growing strongly. Keep and eye on this one! This makes DOCS very considerable for growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year DOCS was profitable.
DOCS had a positive operating cash flow in the past year.
Each year in the past 5 years DOCS has been profitable.
Each year in the past 5 years DOCS had a positive operating cash flow.
1.2 Ratios
The Return On Assets of DOCS (13.67%) is better than 97.37% of its industry peers.
DOCS has a better Return On Equity (16.37%) than 97.37% of its industry peers.
Looking at the Return On Invested Capital, with a value of 15.15%, DOCS belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for DOCS is significantly above the industry average of 5.60%.
The 3 year average ROIC (12.02%) for DOCS is below the current ROIC(15.15%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.67% | ||
| ROE | 16.37% | ||
| ROIC | 15.15% |
ROA(3y)12.35%
ROA(5y)10.68%
ROE(3y)14.41%
ROE(5y)14.17%
ROIC(3y)12.02%
ROIC(5y)17.46%
1.3 Margins
Looking at the Profit Margin, with a value of 31.04%, DOCS belongs to the top of the industry, outperforming 97.37% of the companies in the same industry.
In the last couple of years the Profit Margin of DOCS has grown nicely.
DOCS has a Operating Margin of 36.14%. This is amongst the best in the industry. DOCS outperforms 100.00% of its industry peers.
In the last couple of years the Operating Margin of DOCS has grown nicely.
With an excellent Gross Margin value of 89.35%, DOCS belongs to the best of the industry, outperforming 94.74% of the companies in the same industry.
DOCS's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 36.14% | ||
| PM (TTM) | 31.04% | ||
| GM | 89.35% |
OM growth 3Y11.94%
OM growth 5Y35.03%
PM growth 3Y43.8%
PM growth 5Y113.48%
GM growth 3Y1.71%
GM growth 5Y0.47%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), DOCS is creating some value.
DOCS has less shares outstanding than it did 1 year ago.
DOCS has more shares outstanding than it did 5 years ago.
There is no outstanding debt for DOCS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 19.44 indicates that DOCS is not in any danger for bankruptcy at the moment.
DOCS has a better Altman-Z score (19.44) than 97.37% of its industry peers.
DOCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 19.44 |
ROIC/WACC1.41
WACC10.75%
2.3 Liquidity
DOCS has a Current Ratio of 6.20. This indicates that DOCS is financially healthy and has no problem in meeting its short term obligations.
DOCS's Current ratio of 6.20 is amongst the best of the industry. DOCS outperforms 89.47% of its industry peers.
A Quick Ratio of 6.20 indicates that DOCS has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.20, DOCS belongs to the top of the industry, outperforming 89.47% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.2 | ||
| Quick Ratio | 6.2 |
3. Growth
3.1 Past
DOCS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.14%, which is quite impressive.
The Earnings Per Share has been growing by 81.49% on average over the past years. This is a very strong growth
The Revenue has grown by 13.44% in the past year. This is quite good.
Measured over the past years, DOCS shows a very strong growth in Revenue. The Revenue has been growing by 40.87% on average per year.
EPS 1Y (TTM)30.14%
EPS 3Y81.49%
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)13.44%
Revenue growth 3Y31.96%
Revenue growth 5Y40.87%
Sales Q2Q%6.39%
3.2 Future
The Earnings Per Share is expected to grow by 12.92% on average over the next years. This is quite good.
DOCS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.90% yearly.
EPS Next Y5.59%
EPS Next 2Y7.32%
EPS Next 3Y11.01%
EPS Next 5Y12.92%
Revenue Next Year8.12%
Revenue Next 2Y8.58%
Revenue Next 3Y9.3%
Revenue Next 5Y10.9%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
DOCS is valuated quite expensively with a Price/Earnings ratio of 29.64.
86.84% of the companies in the same industry are more expensive than DOCS, based on the Price/Earnings ratio.
DOCS's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 24.41.
Based on the Price/Forward Earnings ratio of 28.07, the valuation of DOCS can be described as expensive.
Based on the Price/Forward Earnings ratio, DOCS is valued cheaper than 81.58% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 20.59, DOCS is valued a bit more expensive.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.64 | ||
| Fwd PE | 28.07 |
4.2 Price Multiples
84.21% of the companies in the same industry are more expensive than DOCS, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, DOCS is valued a bit cheaper than 73.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 29.29 | ||
| EV/EBITDA | 20.69 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates DOCS does not grow enough to justify the current Price/Earnings ratio.
DOCS has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)5.31
PEG (5Y)N/A
EPS Next 2Y7.32%
EPS Next 3Y11.01%
5. Dividend
5.1 Amount
DOCS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
DOXIMITY INC-CLASS A
NYSE:DOCS (7/26/2024, 7:25:30 PM)
After market: 28.16 0 (0%)28.16
+0.14 (+0.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.22B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.64 | ||
| Fwd PE | 28.07 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)5.31
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.67% | ||
| ROE | 16.37% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 36.14% | ||
| PM (TTM) | 31.04% | ||
| GM | 89.35% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.2 | ||
| Quick Ratio | 6.2 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)30.14%
EPS 3Y81.49%
EPS 5Y
EPS Q2Q%
EPS Next Y5.59%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)13.44%
Revenue growth 3Y31.96%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y